Rising Antibiotic Resistance: A Looming Crisis We Can't Ignore

3dk
Rising Antibiotic Resistance: A Looming Crisis We Can't Ignore
  • Blog Yazısı

Antimicrobial resistance (AMR) has reached a critical point: it's now one of the top 10 global public health threats, as highlighted by the World Health Organization (WHO). In 2019 alone, drug-resistant infections were behind a staggering 4.95 million deaths worldwide, with low- and middle-income countries (LMICs) bearing the brunt of this crisis. What makes this particularly alarming is the projection that, without intervention, AMR could be responsible for 10 million deaths annually by 2050. This paper, dedicated to AMR and published in PLOS Medicine, delves deep into the multifaceted dynamics and challenges posed by this ever-evolving threat.

The surge in antibiotic usage is a significant driver of AMR. Between 2000 and 2015, the global use of antibiotics spiked by 65%, predominantly fueled by increased usage in LMICs. Bacteria, being the complex organisms they are, can transfer DNA at remarkable rates, acquiring resistant mechanisms in the process. This phenomenon, which often occurs without any apparent cost to the bacteria, highlights the complexity of tackling AMR. Unlike earlier beliefs, the presence of antibiotics might not directly influence the transfer of bacterial DNA but can select for newly acquired resistant mechanisms. Additionally, AMR is not just a human health issue; it's a comprehensive One-Health problem that extends to animals and the environment. Inadequate access to water, sanitation, and hygiene (WASH), coupled with limited access to cost-effective diagnostics and appropriate antibiotics, has exacerbated the spread of AMR, particularly in LMICs.

Neonates and infants are especially vulnerable to antibiotic-resistant infections. A comprehensive global prospective study of neonatal sepsis (NeoOBS), which spanned 11 countries across 4 continents, highlighted Klebsiella pneumoniae as the leading pathogen causing neonatal sepsis. The mortality rates associated with this pathogen ranged between 10-12%, and the rates were even higher when blood cultures tested positive. Alarmingly, in this cohort, over 200 different antibiotic combinations were used for 3,204 cases of neonatal sepsis, with significant deviations from WHO-recommended regimens and high usage levels of last-resort antibiotics like colistin. These findings underscore the pressing need for urgent trials to minimize AMR by identifying novel antibiotic regimens.

Tüm Reklamları Kapat

Inappropriate antibiotic prescriptions aren't limited to hospital settings. Data from a prospective, community-based cohort study conducted between 2012 and 2018 across Cambodia, Madagascar, and Senegal revealed extensive and inappropriate antibiotic prescribing among pediatric outpatients. The study found that 76.5% of consultations resulting in antibiotic prescriptions were deemed unnecessary. Diseases like rhinopharyngitis, gastroenteritis, and uncomplicated bronchiolitis accounted for the majority of these inappropriate prescriptions. Furthermore, children older than three months living in rural areas were more likely to receive these unwarranted prescriptions, emphasizing the need for local programs to optimize antibiotic prescribing at the community level in LMICs.

A systematic review of 109 studies on bloodstream infections in hospitalized patients from LMICs revealed several WHO’s critical and high-priority pathogens were linked to heightened mortality, prolonged hospital stays, and higher ICU admissions and costs. There was considerable variation between WHO regions, income groups, and pathogen-drug combinations. Despite the substantial disease and economic burden posed by AMR in LMICs, a lack of data on bloodstream infections from these regions hinders the implementation of specific policies. Countries need to monitor and record antibiotic usage to tackle this issue effectively. Point prevalence surveys indicate that annually, about 136 million hospital-associated resistant infections (HARIs) are caused by high-priority pathogens, with the highest burdens found in China, Pakistan, and India.

High-income countries haven't been spared either. Prolonged antibiotic misuse has given rise to superbugs, such as methicillin-resistant Staphylococcus aureus (MRSA). Antibiotic stewardship programs often shorten treatment durations to reduce the prevalence of antimicrobial-resistant bacteria. However, the relationship between treatment duration and the prevalence of resistant bacteria remains unclear. Healthcare facilities, particularly during the COVID-19 pandemic, became hotspots for AMR pathogens due to increased demand for healthcare access and disorganized service delivery, which compromised standard infection control measures. Research revealed a 14% increase in bacterial colonization and a 10% increase in AMR rates during surges in COVID-19 cases. Conversely, COVID-19 control measures inadvertently limited bacterial spread, reducing the patient acquisition of drug-resistant bacteria by 28%.

Vaccination has been proven effective in preventing the spread of infectious diseases, but tackling AMR requires more than just a single vaccination program. WHO has called for vaccines targeting resistant microbial species, particularly Klebsiella pneumoniae. A modeling study examined a hypothetical K. pneumoniae maternal vaccine's impact on neonatal sepsis infections and mortality, estimating that such vaccination could prevent 80,258 neonatal deaths and 399,015 cases of neonatal sepsis worldwide annually. The largest relative benefits were predicted in Africa and Southeast Asia, countries like Sierra Leone, Mali, Niger, and Bangladesh, where vaccination could avert over 6% of all neonatal deaths.

This comprehensive review highlights the critical nature of standardized reporting for AMR infections and antibiotic usage. Improved diagnostics are paramount in understanding prevalence and resistance patterns at national, regional, and local levels. Standardized reporting would significantly enhance antimicrobial stewardship programs and guidelines for antimicrobial use. With the upcoming high-level United Nations meeting in September 2024, there’s an urgent need for world leaders and policymakers to recognize the significance of AMR and ensure adequate investments in innovative affordable vaccines, antimicrobial agents, diagnostics, and reporting systems.

The COVID-19 pandemic has starkly reminded us that we live in an interconnected world, and what transpires in one part of the globe can rapidly impact another. Since December 2019, the pandemic has been attributed to 3.2 million deaths, costing the global economy approximately $17 trillion. However, if left unchecked, AMR is projected to outpace this, with potential annual deaths reaching 10 million and an estimated global economic cost of over $100 trillion by 2050. These figures underscore the urgent need to address AMR, which poses a threat far greater than that of COVID-19.

Rastgele Yazıya Git
3
Alt Başlıklar
Bu Blog Yazısı Sana Ne Hissettirdi?
  • Muhteşem!
    Muhteşem!
    0
  • Tebrikler!
    Tebrikler!
    0
  • Bilim Budur!
    Bilim Budur!
    0
  • Mmm... Çok sapyoseksüel!
    Mmm... Çok sapyoseksüel!
    0
  • Güldürdü
    Güldürdü
    0
  • İnanılmaz
    İnanılmaz
    0
  • Umut Verici!
    Umut Verici!
    0
  • Merak Uyandırıcı!
    Merak Uyandırıcı!
    0
  • Üzücü!
    Üzücü!
    0
  • Grrr... *@$#
    Grrr... *@$#
    0
  • İğrenç!
    İğrenç!
    0
  • Korkutucu!
    Korkutucu!
    0

Yorumlar 0

Evrim Ağacı'na her ay sadece 1 kahve ısmarlayarak destek olmak ister misin?

Şu iki siteden biriyle hemen destek olabilirsin:

kreosus.com/evrimagaci | patreon.com/evrimagaci

Çıktı Bilgisi: Bu sayfa, Evrim Ağacı yazdırma aracıyla 22.11.2026 17:53:27 tarihinde oluşturuldu. Evrim Ağacı'ndaki içerikleri birden fazla editör sürekli gözden geçiriyor, güncelliyor ve geliştiriyor. Bu çıktıdan sonraki güncellemeleri görmek ve içeriğin en güncel hâlini okumak için şu adrese git: evrimagaci.org/s/17690

İçerik Kullanım İzinleri: Evrim Ağacı'ndaki yazılı içerikler orijinallerine hiçbir şekilde dokunulmadığı sürece izin alınmaksızın paylaşılabilir, kopyalanabilir, yapıştırılabilir, çoğaltılabilir, basılabilir, dağıtılabilir, yayılabilir, alıntılanabilir. Ancak bu içeriklerin hiçbiri izin alınmaksızın değiştirilemez ve değiştirilmiş hâlleri Evrim Ağacı'na aitmiş gibi sunulamaz. Benzer şekilde, içeriklerin hiçbiri, söz konusu içeriğin açıkça belirtilmiş yazarlarından ve Evrim Ağacı'ndan başkasına aitmiş gibi sunulamaz.

Hemen Paylaş
Bu blog yazısını sevdin mi?
Paylaşarak başkalarına da ilham ol.
Keşfetmeye Devam Et